Valuation: Sygnis SA

Market Cap 33.28M 8.75M 7.63M 7.2M 6.54M 12.25M 839M 12.3M 86.25M 427M 32.85M 32.12M 1.37B P/E 2024 *
-
P/E 2025 174x
Enterprise Value 35.99M 9.46M 8.25M 7.79M 7.07M 13.25M 907M 13.3M 93.27M 461M 35.52M 34.74M 1.48B EV / Sales 2024
1.44x
EV / Sales 2025 5.47x
Free-Float
38.51%
Yield 2024 *
-
Yield 2025 -
1 day+2.62%
1 week-5.12%
Current month+3.03%
1 month-10.13%
3 months-24.72%
6 months-42.70%
Current year-52.78%
1 week 0.89
Extreme 0.89
1.07
1 month 0.89
Extreme 0.89
1.14
Current year 0.89
Extreme 0.89
3
1 year 0.89
Extreme 0.89
3.8
3 years 0.28
Extreme 0.28
3.8
5 years 0.28
Extreme 0.28
3.8
10 years 0.18
Extreme 0.176
3.8
Manager TitleAgeSince
Chief Executive Officer - 2016-12-31
Chief Tech/Sci/R&D Officer - 2018-10-31
Sales & Marketing - 2019-12-31
Director TitleAgeSince
Chairman - -
Chairman - 2025-10-28
Director/Board Member - 2025-10-28
Change 5-day change 1-year change 3-year change Capi.($)
+2.62%-5.12%-51.43%+2.00% 8.75M
+0.11%+2.71%+0.44%+26.85% 46.28B
-1.12%+1.78%+42.30%+27.55% 43.85B
-3.04%-6.29%+338.56%+515.97% 40.93B
-0.74%+1.25%+4.92%+67.98% 39.89B
-0.50%+0.67%+10.29%+41.28% 29.5B
-0.46%+4.22%+22.81%+139.44% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.19%+38.68% 15.22B
-3.14%+31.91%-11.79% - 14.05B
Average -0.78%+3.61%+42.03%+107.47% 26.24B
Weighted average by Cap. -1.10%+1.87%+68.04%+130.90%

Financials

2024 2025
Net sales 9.8M 2.58M 2.25M 2.12M 1.93M 3.61M 247M 3.62M 25.4M 126M 9.67M 9.46M 404M 11.33M 2.98M 2.6M 2.45M 2.23M 4.17M 286M 4.19M 29.37M 145M 11.19M 10.94M 467M
Net income -11.29M -2.97M -2.59M -2.44M -2.22M -4.16M -285M -4.17M -29.26M -145M -11.14M -10.9M -466M 404K 106K 92.62K 87.46K 79.42K 149K 10.19M 149K 1.05M 5.18M 399K 390K 16.67M
Net Debt 4.3M 1.13M 985K 930K 844K 1.58M 108M 1.59M 11.14M 55.08M 4.24M 4.15M 177M 2.71M 712K 621K 586K 532K 997K 68.3M 1M 7.02M 34.73M 2.67M 2.61M 112M
Logo Sygnis SA
Sygnis SA is a Poland-based company primarily engaged in the Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.
Employees
24
Date Price Change Volume
26-09-18 PLN 1.020 +2.62% 31,023
26-09-17 PLN 0.9940 +10.44% 39,337
26-09-16 PLN 0.9000 -7.22% 85,806
26-09-15 PLN 0.9700 -2.81% 22,376
26-09-14 PLN 0.9980 -7.16% 66,015
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!